InspireMD signals potential FDA decisions in Q4 2026 while targeting $9M in annual cost savings (NASDAQ:NSPR)
· seekingalpha.com
InspireMD (NSPR) Q2 2026 earnings call recap: recall impact, 21% international growth, Q4 FDA decision outlook, and cost cuts.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...